Ndclnh-mytho-usa.org



Kính thưa quí bạn

Tôi làm phiền buộc phải gổi các bạn cái email ngắn. Tin nầy mới loan ra vài giờ trước đây. (30-Nov-2018)

Thêm vài món thuốc hạ áp huyết thông dụng bị thu hồi vì chứa chất có thể gây ung thư: amlodipine, valsartan, and hydrochlorothiazide.

Đây là mấy thứ mà người có tuổi thường đang uống.

[pic]

Đây là những loại thuốc bạn già chúng ta đang uống, xin liện lạc ngay với bác sĩ và dược sĩ trước khi ngưng. Ngưng ngang vì tin nầy nguy hiểm hơn.

HCD 30-Nov-2018

Two more blood pressure drugs recalled for potential cancer risk

Brett Molina, USA TODAY Published 6:07 a.m. ET Nov. 30, 2018 | Updated 11:19 a.m. ET Nov. 30, 2018

Teva Pharmaceuticals has launched a voluntary recall into two drugs used to treat high blood pressure as more medications face concerns over a possible cancer risk. USA TODAY

[pic]

(Photo: Alison Young, USA TODAY)

CONNECTTWEETLINKEDINCOMMENTEMAILMORE

Teva Pharmaceuticals has launched a voluntary recall into two drugs used to treat high blood pressure as yet more medications face concerns over a possible cancer risk.

In a statement from Teva posted by the Food and Drug Administration, the recall affects all lots of combination tablets featuring the drugs amlodipine and valsartan and another combo drug featuring amlodipine, valsartan, and hydrochlorothiazide.

The drugs could contain an impurity called N-nitroso-diethylamine (NDEA), which has been classified as a possible human carcinogen, the FDA said.

Patients taking either drugs should contact their doctor or pharmacist for advice or alternative treatments. Stopping the drugs immediately with no comparable alternative could pose a greater risk to patients' health, said Teva.

More: Want more news like this? Subscribe to get the Daily Briefing in your inbox.

Customers and patients with questions can contact Teva by phone at 888-838-2872, or email at druginfo@.

In August, the FDA announced an expanded recall of valsartan because products may contain the impurity. Last month, two more recalls were announced: one for the drug irbesartan and a second recall for losartan potassium hydrochlorothiazide tablets.

During an interview in November with USA TODAY, FDA commissioner Scott Gottlieb said the blood pressure drug recalls reflect an increased focus on drug quality to ensure no impurities are present.

HCD (30-Nov-2018)

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download